Category: unreliable findings

Authors retract 2016 cancer study when data don’t align with figures

cell-death-and-differentiationResearchers have retracted a 2016 cancer study, citing discrepancies between the data and images presented in the paper. 

Although the retraction notice itself contains relatively little information, we’ve obtained a letter from the last author — Jun-Li Luo of The Scripps Research Institute in Jupiter, Florida — to the editor-in-chief of Cell Death and Differentiation that says a bit more. 

According to the letter, after receiving the anonymous email, Luo conducted an investigation, contacting co-authors who contributed each of the figures in question. Although Luo writes that he has no reason to suspect fraud, the researchers were not able to provide some of the original data.

PubPeer commenters have questioned figures 1, 3, 4, 5, 6 and 7 in the study, “IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy.”

In the letter, Luo tells Gerry Melino, co-editor-in-chief of the journal from the University of Leicester, UK, that figures 3D and 3E were provided by the study’s first author, Xing Fang, adding: Continue reading Authors retract 2016 cancer study when data don’t align with figures

Correction cites “unreliable” data in paper by researchers at center of Duke lawsuit

Journal of Biological ChemistryA researcher charged with embezzlement — and now the subject of a multi-million dollar lawsuit — has earned another correction, again citing “unreliable” data.

But this doesn’t appear to be a run-of-the-mill correction notice.

Firstly, it affects a paper co-authored by Erin Potts-Kant and William Foster, former Duke employees now being sued (along with Duke) for including fraudulent data in $200 million worth of federal grants. Secondly, the notice in the Journal of Biological Chemistry is four paragraphs long, and includes six figures — it would normally be considered a “mega-correction.” But lastly, even though the notice is labeled a “correction,” it’s not immediately apparent which aspects of the paper are being changed.

Here are some excerpts from the newest notice: Continue reading Correction cites “unreliable” data in paper by researchers at center of Duke lawsuit

Biologist loses second paper — again, for unvalidated figures

Cellular SignallingA researcher at Case Western Reserve University in Ohio has retracted a second paper after a review found the figures didn’t match the original data.  

Last year, we reported on a previous retraction of a paper co-authored by biologist Alan Levine in Inflammatory Bowel Diseases, which was pulled for the exact same reason; even the retraction notices use similar language. The first author on both papers is Debasmita Mandal, also listed at Case Western Reserve University.

Here’s the retraction notice for “REDOX regulation of IL-13 signaling in intestinal epithelial cells: usage of alternate pathways mediates distinct gene expression patterns,” published by Cellular Signalling: Continue reading Biologist loses second paper — again, for unvalidated figures

Author objects to retraction of heart study, implies industry played role

JACC

The Journal of the American College of Cardiology (JACC) has retracted a recently published paper that questioned the effectiveness of a treatment for irregular heartbeat, against the last author’s wishes. 

Andrea Natale, the study’s last and corresponding author and Executive Medical Director of Texas Cardiac Arrhythmia at Austin, took to social media today to express his frustration in the retraction of the July paper, which showed electrical rotors were less effective at fixing irregular heartbeat than other treatments. On Twitter, Natale implied industry played a role in its demise.

However, according to the retraction notice, the paper was felled by problems with randomization; Natale has admitted that some patients were removed from the analysis after one center included them incorrectly.

Here’s the retraction notice for “Impact of Rotor Ablation in Nonparoxysmal Atrial Fibrillation Patients Results From the Randomized OASIS Trial:” Continue reading Author objects to retraction of heart study, implies industry played role

Journal flags two papers by prominent diabetes researcher, more questioned on PubPeer

DiabetesDiabetes has issued two expressions of concern (EOCs) for papers co-authored by leading diabetes researcher Kathrin Maedler, adding to her previous count of one retraction and three corrections.

Both papers were questioned on PubPeer, alongside several others co-authored by Maedler, who is based at the University of Bremen in Germany. As we previously reported, PubPeer comments have led to one retraction for Maedler in the Journal of Biological Chemistry (JBC), and corrections in various other journals.

One of those corrections has now earned an EOC from Diabetes, which also extends to the original paper. Here are the notices, which asks the University of Bremen to investigate further:  Continue reading Journal flags two papers by prominent diabetes researcher, more questioned on PubPeer

Beg pardon? Researchers pull cancer paper because, well, um, you see …

dovepressWe’ve been writing about retractions for six years, and things tend to fall into easily recognizable categories — plagiarism, fabricated data, rigged peer review, etc.

So it’s always interesting to come across a notice sui generis, such as one that appeared in July in OncoTargets and Therapy, a Dove title, about a new way to detect tumor markers.

According to the retraction notice:

Continue reading Beg pardon? Researchers pull cancer paper because, well, um, you see …

Researcher denied PhD after “recklessly” committing misconduct

Molecular PharmacologyA doctoral student at the University of Houston in Texas will not receive his PhD, following an institutional investigation into his work.

Mousa Abkhezr, the researcher in question, is no longer enrolled at the University of Houston, his former supervisor told us.

In June, the probe into papers co-authored by Abkhezr resulted in the retraction of a study in the American Journal of Physiology – Renal Physiology (AJP). Now, his ex-supervisor, Stuart Dryer, has pulled two more papers co-authored by the pair in Molecular Pharmacology.

Here’s the retraction notice for “Angiotensin II and Canonical Transient Receptor Potential-6 Activation Stimulate Release of a Signal Transducer and Activator of Transcription 3–Activating Factor from Mouse Podocytes:” Continue reading Researcher denied PhD after “recklessly” committing misconduct

Institute director loses third paper following investigation

Screen Shot 2016-06-07 at 4.16.03 PM

An autism researcher is retracting a paper she shared with the director of a New York institute, following a misconduct investigation.

In 2011, suspicions raised by peer reviewers triggered the investigation into several papers by Xiaohong Li at the Institute for Basic Research in Developmental Disabilities (IBR) in New York. The probe concluded in 2013 that there was no evidence of misconduct, but the committee recommended the institute review all relevant papers. This additional review led to the latest retraction, the result of problems with figures which “underpin the conclusions of the study.”

This is Li’s third retraction, all of which she shares with W. Ted Brown, the director of  IBR. The pair lost two articles in 2013.

Here’s the retraction notice for “Alteration of astrocytes and Wnt/beta-catenin signaling in the frontalcortex of autistic subjects,” published in the Journal of Neuroinflammation: 

Continue reading Institute director loses third paper following investigation

Investigation raises questions about top cancer researcher’s work

Journal of Pathology

A prominent pancreatic cancer researcher has lost a meeting abstract and corrected a Nature paper following an institutional investigation.

Queen Mary University of London determined that, in an abstract by Thorsten Hagemann, “elements of the study summarised by this abstract are not reliable.” Hagemann has recently issued a correction to a 2014 Nature paper he co-authored, which also cited the Queen Mary University of London (QMUL) investigation, noting there was “reason to question the provenance of the data.”

Hagemann is currently the medical director of Immodulon Therapeutics, and has long been recognized for his work in the field, including a three-year grant of £180,000 from the Pancreatic Cancer Research Fund in 2013.

Here’s the retraction notice from the The Journal of Pathology, regarding an abstract from the 7th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland: Continue reading Investigation raises questions about top cancer researcher’s work

Trump vs. trump: Does the candidate affect the use of trump cards in Bridge?

Jonathan
Jonathan Falk
Andrew Gelman
Andrew Gelman

Did that headline make sense? It isn’t really supposed to – it’s a sum-up of a recent satirical paper by Columbia statistician Andrew Gelman and Jonathan Falk of NERA Economic Consulting, entitled “NO TRUMP!: A statistical exercise in priming.” The paper – which they are presenting today during the International Conference on Machine Learning in New York City – estimates the effect of the Donald Trump candidacy on the use of no wild cards (known as trump cards) in the game of bridge. But, as they told us in an interview, the paper is about more than just that.

Retraction Watch: You have a remarkable hypothesis: “Many studies have demonstrated that people can be unconsciously goaded into different behavior through subtle psychological priming. We investigate the effect of the prospect of a Donald Trump presidency on the behavior of the top level of American bridge players.” Can you briefly explain your methodology, results and conclusions?  Continue reading Trump vs. trump: Does the candidate affect the use of trump cards in Bridge?